Stocktoria
LB PHARMACEUTICALS INC LBRX
LB PHARMACEUTICALS INC (LBRX) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | 2/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About LB PHARMACEUTICALS INC
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
FAQ
Is LBRX financially healthy?
LB PHARMACEUTICALS INC's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does LBRX pay a dividend?
No, LB PHARMACEUTICALS INC does not currently pay a dividend.
How profitable is LBRX?
In FY2025, LB PHARMACEUTICALS INC had a return on equity of -8.4%.
What is the analyst price target for LBRX?
The average Wall-Street price target for LB PHARMACEUTICALS INC is $45.00, about 0.8% below the recent price, from 6 analysts (consensus: strong buy).
Is LBRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LB PHARMACEUTICALS INC: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.